News Article

Three New Orleans Founded Bio-Startups Win SBIR Grants

Henley Ion – $950,000 NIH Direct to Phase II SBIR award to develop a micronized electrostatic precipitator for next-generation respiratory protection against pathogenic aerosols.

BioAesthetics – $875,000 through an NIH Phase II SBIR to develop PHMB-Impregnated acellular biologic grafts for treatment of third-degree burns.

South Rampart Pharma, Inc. – awarded FDA “Fast-Track Designation” as well as an NIH (NINDS) Commercialization Readiness Pilot Program (CRP) grant, following a 2022 NIH (NINDS) Fast-Track Small Business Technology Transfer (STTR) Commercialization Grant of $1.9 million.